WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML

In this trial, HLA-A2+ patients with active AML are vaccinated with a peptide from the leukemia-associated antigen WT1 together with immunological adjuvants keyhole limpet hemocyanin (KLH) as T-helper protein and granulocyte macrophage colony stimulating factor (GM-CSF) 4 times bi-weekly, then monthly.

In this phase II trial HLA-A2+ patients with active AML without curative treatment option are vaccinated with WT1 126-134 peptide mixed with adjuvant KLH as T-helper protein and GM-CSF 4 times bi-weekly, then monthly.

Inclusion Criteria:

• AML or myelodysplastic syndromes (MDS)
• Partial response (PR) or complete response (CR) or smoldering course without option for allogeneic stem cell transplantation
• HLA-A2+
• WT1-expression in bone marrow